Inventor
GAMACHE DANIEL A
US38 patents
⚠️ This page may combine multiple inventors who share the name “GAMACHE DANIEL A”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
ALCON INC
9 patentsUS6872382B1Mar 29, 2005
Use of selective PDE IV inhibitors to treat dry eye disorders
ALCON INC64 citations96
US6645978B1Nov 11, 2003
Lipoxin A4 and its analogs for the treatment of dry eye
ALCON INC39 citations92
US6645994B1Nov 11, 2003
Method of treating dry eye disorders
ALCON INC10 citations74
US6638976B2Oct 28, 2003
Method of treating neurodegenerative disorders of the retina and optic nerve head
ALCON INC10 citations74
US7923471B2Apr 12, 2011
Method of treating dry eye disorders and uveitis
ALCON INC3 citations63
US7026296B2Apr 11, 2006
Methods of treating dry eye disorders
ALCON INC5 citations63
US6825232B2Nov 30, 2004
Use of hydroxyeicosatetraenoic acid compounds to treat ophthalmic inflammatory disorders
ALCON INC7 citations63
US6696453B2Feb 24, 2004
Use of NF-κB inhibitors to treat dry eye disorders
ALCON INC2 citations63
US7879905B2Feb 1, 2011
5,6,7-trihydroxyheptanoic acid and analogs for the treatment of ocular diseases and diseases associated with hyperproliferative and angiogenic responses
ALCON INC0 citations52
ALCON LAB INC
8 patentsUS6174878B1Jan 16, 2001
Topical use of kappa opioid agonists to treat otic pain
ALCON LAB INC71 citations96
US5811438ASep 22, 1998
Esters and amides of non-steroidal anti-inflammatory carboxylic acids which may be used as anti-oxidants, 5-lipoxygenase inhibitors and non-steroidal anti-inflammatory products
ALCON LAB INC53 citations96
US5643943AJul 1, 1997
Systemic administration of esters and amides of antioxidants which may be used as antioxidant prodrug therapy for oxidative and inflammatory pathogenesis
ALCON LAB INC47 citations96
US6191126B1Feb 20, 2001
Topical use of κ opioid agonists to treat ocular pain
ALCON LAB INC21 citations92
US5686488ANov 11, 1997
Polyethoxylated castor oil products as anti-inflammatory agents
ALCON LAB INC33 citations92
US6174914B1Jan 16, 2001
Method of inhibiting cytokine release from human ocular cells
ALCON LAB INC10 citations71
US6225332B1May 1, 2001
Compositions containing histamine H2 agonists and methods of use in treating allergy and inflammation
ALCON LAB INC4 citations63
US6274160B1Aug 14, 2001
Methods of use of histamine H2 agonists in treating dry eye
ALCON LAB INC0 citations52
YANNI JOHN M
5 patentsUS8222227B2Jul 17, 2012
RNAi-mediated inhibition of histamine receptor H1-related conditions
YANNI JOHN M6 citations83
US8673873B1Mar 18, 2014
RNAi-mediated inhibition of phosphodiesterase type 4 for treatment of cAMP-related ocular disorders
YANNI JOHN M1 citations62
US8618278B2Dec 31, 2013
RNAi-mediated inhibition of histamine receptor H1-related conditions
YANNI JOHN M2 citations62
US8865671B2Oct 21, 2014
RNAi-mediated inhibition of spleen tyrosine kinase-related inflammatory conditions
YANNI JOHN M0 citations51
US8541389B2Sep 24, 2013
RNAi-mediated inhibition of tumor necrosis factor α-related conditions
YANNI JOHN M0 citations50
ARROWHEAD RES CORP
5 patentsUS9206428B2Dec 8, 2015
RNAi-mediated inhibition of histamine receptor H1-related conditions
ARROWHEAD RES CORP2 citations63
US9453220B2Sep 27, 2016
RNAi-mediated inhibition of phosphodiesterase type 4 for treatment of cAMP-related ocular disorders
ARROWHEAD RES CORP2 citations58
US9745585B2Aug 29, 2017
RNAi-mediated inhibition of histamine receptor H1-related conditions
ARROWHEAD RES CORP0 citations52
US9371529B2Jun 21, 2016
RNAi-mediated inhibition of spleen tyrosine kinase-related inflammatory conditions
ARROWHEAD RES CORP0 citations52
US9447419B2Sep 20, 2016
RNAi-mediated inhibition of tumor necrosis factor α-related conditions
ARROWHEAD RES CORP0 citations51
ALCON RES LTD
4 patentsUS8017592B2Sep 13, 2011
RNAi-mediated inhibition of histamine receptor H1-related conditions
ALCON RES LTD5 citations74
US8048863B2Nov 1, 2011
RNAi-mediated inhibition of spleen tyrosine kinase-related inflammatory conditions
ALCON RES LTD3 citations63
US7732421B2Jun 8, 2010
RNAI-mediated inhibition of tumor necrosis factor α-related conditions
ALCON RES LTD4 citations62
US9533053B2Jan 3, 2017
High concentration olopatadine ophthalmic composition
ALCON RES LTD0 citations49
ALCON UNIVERSAL LTD
3 patentsUS6429227B1Aug 6, 2002
Hydroxyeicosatetraenoate salts, compositions and methods of use in treating dry eye disorders
ALCON UNIVERSAL LTD20 citations91
US6353022B1Mar 5, 2002
Compositions containing hydroxyeicosatetraenoic acid derivatives and methods of use in treating dry eye disorders
ALCON UNIVERSAL LTD38 citations88
US6353012B1Mar 5, 2002
15-Hydroxyeicosatetraenoic acid-related compounds and methods of use
ALCON UNIVERSAL LTD8 citations74